At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 15 enrolled
Drug / intervention
fluticasone and salmeteroldrug
Likely dose
fluticasone and salmeterol 220 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of the Mechanism of Synergism Between Fluticasone (FP) and Salmeterol in Preventing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
In Brief
A Phase 1 clinical trial evaluating fluticasone and salmeterol for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the blood and airway of subjects with mild to moderate COPD while undergoing standard treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited States
CollaboratorsGlaxoSmithKline
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2005
First PostedJun 2005
Primary CompletionSep 2009
Study CompletionOct 2009
TodayJul 2026
First PostedJun 29, 2005
Enrollment StartJan 1, 2005
Primary CompletionSep 1, 2009
Study CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 21.0 years ago
Interventions
fluticasone and salmeteroldrug
1. will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID 2. will start with salmeterol 50 mcg BID first and then crossover to combination therapy with fluticasone 220 mcg BID.